Difference between revisions of "Dactinomycin (Cosmegen)"
Jump to navigation
Jump to search
m |
|||
Line 21: | Line 21: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 12/10/1964: Initial FDA approval | * 12/10/1964: Initial FDA approval | ||
+ | * Unclear date: Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of [[Wilms tumor]], childhood [[rhabdomyosarcoma]], [[Ewing sarcoma]] and metastatic, nonseminomatous [[testicular cancer]]. | ||
+ | * Unclear date: Approved as a single agent, or as part of a combination chemotherapy regimen, for the treatment of [[gestational trophoblastic neoplasia]]. | ||
+ | * Unclear date: Approved as a component of regional perfusion for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. | ||
==Also known as== | ==Also known as== |
Revision as of 02:14, 5 August 2019
General information
Class/mechanism: Antibiotic oncologic, intercalates between guanine and cytosine DNA base pairs, inhibiting DNA and RNA synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Endometrial cancer
- Ewing sarcoma
- Gestational trophoblastic neoplasia
- Osteosarcoma
- Rhabdomyosarcoma
- Rhabdomyosarcoma
- Wilms tumor
Patient drug information
- Dactinomycin (Cosmegen) patient drug information (Chemocare)[3]
- Dactinomycin (Cosmegen) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/10/1964: Initial FDA approval
- Unclear date: Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of Wilms tumor, childhood rhabdomyosarcoma, Ewing sarcoma and metastatic, nonseminomatous testicular cancer.
- Unclear date: Approved as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia.
- Unclear date: Approved as a component of regional perfusion for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.
Also known as
- Generic names: AC-DE, actinomycin D
- Brand names: Cosmegen, Dacmozen, Lyovac
References
Categories:
- Drugs
- Intravenous medications
- Vesicant chemotherapy
- DNA synthesis inhibitors
- Endometrial cancer medications
- Ewing sarcoma medications
- Gestational trophoblastic neoplasia medications
- Osteosarcoma medications
- Rhabdomyosarcoma medications
- Soft tissue sarcoma medications
- Wilms tumor medications
- FDA approved in 1964
- WHO Essential Cancer Medicine